Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Sep;56(9):681-6.
doi: 10.1136/jcp.56.9.681.

Ki-67 immunocytochemistry in liquid based cervical cytology: useful as an adjunctive tool?

Affiliations

Ki-67 immunocytochemistry in liquid based cervical cytology: useful as an adjunctive tool?

S Sahebali et al. J Clin Pathol. 2003 Sep.

Abstract

Aims: To test the ability of Ki-67 to detect cytological lesions in a screening setting and its use as a surrogate marker of human papillomavirus (HPV) infection.

Methods: A study of liquid based cytology, HPV DNA testing by MY09/MY11 consensus polymerase chain reaction (PCR), type specific PCRs, and Ki-67 immunocytochemistry on a randomly selected series of 147 patients.

Results: Comparison of the number of Ki-67 immunoreactive cells/1000 cells in the different cytological groups showed that the HSIL group yielded a significantly higher mean count than did the other groups. The number of Ki-67 immunoreactive cells/1000 cells was significantly higher in HPV-16 positive samples than in samples containing infections with other high risk types. Receiver operating characteristic curves indicated a test accuracy (area under curve) of 0.68, 0.72, and 0.86 for atypical squamous cells of undetermined significance (ASCUS), low grade squamous intraepithelial lesions (LSIL), and high grade squamous intraepithelial lesions (HSIL), respectively. Thresholds for 95% sensitivity were 0.07, 0.08, and 0.15 Ki-67 immunopositive cells/1000 cells for ASCUS, LSIL and HSIL, respectively. The threshold for 95% specificity was 1.9 Ki-67 immunopositive cells/1000 cells.

Conclusions: Ki-67 immunocytochemistry can be applied to liquid based cytology. The accuracy and diagnostic indices of the test are good when compared with those of other techniques. As part of a panel of screening procedures, it could be used as an adjunct to liquid based cytology to identify HSIL, and as a surrogate marker of HPV-16 infection.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Ki-67 immunocytochemistry. A group of immunopositive cells in a high grade squamous intraepithelial lesion case, detail of the nuclear staining pattern.
Figure 2
Figure 2
Ki-67 immunopositivity in cytology. Mean and SEM depicted for each cytological category, given as the number of immunopositive cells/1000 cells. The HSIL group differs significantly from the other groups. ASCUS, atypical squamous cells of undetermined significance; HSIL, high grade squamous intraepithelial lesion; LSIL, low grade squamous intraepithelial lesion; WNL, within normal limits.
Figure 3
Figure 3
Ki-67 immunopositivity in human papillomavirus (HPV) typing. Mean and SEM depicted for HPV-16, other high risk (HR) HPV types, HPV types of unknown malign potential (unknown), and HPV negatives, given as the number of immunopositive cells/1000 cells. The HPV-16 group differs significantly from the other groups.
Figure 4
Figure 4
Receiver operating characteristic curves for Ki-67 immunocytochemistry in three different diagnostic circumstances. ASCUS, a diagnosis of atypical squamous cells of undetermined significance or worse; LSIL, a diagnosis of low grade squamous intraepithelial lesion or worse; HSIL, a diagnosis of high grade squamous intraepithelial lesion.

Similar articles

Cited by

References

    1. Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365–71. - PubMed
    1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12–19. - PubMed
    1. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244–65. - PMC - PubMed
    1. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. J Natl Cancer Inst 1995;87:796–802. - PubMed
    1. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423–8. - PubMed

Publication types